It's a small revolution in health 2.0. On June 11, at the end of a long process, a therapeutic web application dedicated to lung cancer, Moovcare, obtained its registration on the list of products reimbursable by Health Insurance. The epilogue of certification by the High Health Authority and long negotiations with the Economic Committee for Health Products (Ceps), responsible for setting the price of reimbursable medicines and medical devices.
Only the application decree is missing for this innovation to complete the therapeutic arsenal of the second deadliest cancer, behind that of the prostate, and of which 430,000 new cases are detected each year.
"It was a long and hard negotiation because there were no comparable products to serve as a basis for calculating the price," explains Ayala Bliah, managing director of Sivan, the digital platform that markets Moovcare. We had to do education on digital therapy, demonstrate the gain for health insurance and for patients. The price awarded in the end is lower than our requests, but this recognition will allow us to deploy our innovation, ”reacts, satisfied, the manager of the platform specializing in the early detection of recurrences and complications. Sivan is now targeting six thousand patients followed by Moovcare within three years, and international development, first in Germany, and in the longer term in the United States.
7.6 months gain in average life expectancy thanks to artificial intelligence
The price awarded by Ceps is 1000 euros. The use of this medical application will be prescribed by the doctor and billed quarterly. At this price, "Health Insurance saves 10% of the cost of treatment," says Ayala Bliah. The patient who will be prescribed this "digital therapy" by his oncologist or pulmonologist, will receive a weekly alert to fill out an online form of ten questions. The artificial intelligence integrated into the Sivan platform will detect the signal of relapse or complication and alert the healthcare team. Clinical studies of 400 patients have shown an average life expectancy gain of 7.6 months.
“Clearly, after two years, the lung cancer patients who are still alive are 20% more numerous when they used Moovcare”, summarizes doctor Alain Livartowski, oncologist at the Institut Curie who strongly recommended the application as soon as he discovered it. It was during a presentation by its designer, Doctor Fabrice Denis, oncologist at the Jean-Bernard center, in Le Mans (Sarthe).
"I was immediately struck by the acceptability of all the patients," says the Paris doctor. But I feared that the application would depersonalize the consultation; the opposite happened. As we know better what happens at home between two meetings, we can widen the discussion. Because the problem is that when there are signs, sometimes the patient does not pay attention, often he decides to wait for the next appointment, in 3 months, in 6 months, to talk about it. We are wasting time. With the application, at the slightest signal, we can intervene, for example by prescribing a scanner. "
“It pays me” newsletterThe newsletter that improves your purchasing power
Your email address is collected by Le Parisien to allow you to receive our news and commercial offers. Find out more
The creation of Moovcare required six years of work and 10 million euros of investment. Its entry into the list of reimbursable services opens the way to other innovations in digital health. Health Insurance wishes to promote the care and therefore the use of connected medical devices from 2021 "which in certain cases contribute to a marked improvement in the quality of life, even survival", is it written in the project of Social Security budget, but "from which patients do not systematically benefit today", due to administrative dead ends